GPU-based Deep Learning Enhances Drug Discovery Says Startup

By John Russell

May 26, 2016

Sifting the avalanche of life sciences (LS) data for insight is an interesting and important challenge. Many approaches are used with varying success. Recently, improved hardware – primarily GPU-based – and better neural networking schemes are bringing deep learning to the fore. Two recent papers report the use of deep neural networks is superior to typical machine learning (support vector machine model) in sieving LS data for drug discovery and personalized medicine purposes.

The two papers, admittedly driven by a commercial interest (Insilico Medicine), are nevertheless more evidence of deep neural network (DNN) progress in LS research where large datasets with high dimensionality have long been difficult to handle. Using DNN to train models and produce answers is proving quite effective; in these two studies both straightforward and more complicated neural network techniques were used. Snapshot:

Part of what’s interesting here is the broad applicability of the DNN approach. As the authors (listed below) note there are many in silico approaches to drug discovery and disease classification, including efforts to use transcriptional response to predict functional properties of drugs. Neural networks’ natural knack for handling high dimensional data is an important capability in LS. Deep learning has already proven very valuable in a range of activities spanning simple image recognition to physics applications.

Broadly, neural networks try to emulate the way biological neural networks operate. Artificial neural networks are generally presented as systems of interconnected “neurons” which exchange messages between each other. The connections have numeric weights that can be tuned based on experience, making neural nets adaptive to inputs and capable of learning. In essence they can be trained to understand and solve classes of problems.

For example, a neural network for handwriting recognition might be defined by a set of input neurons that are activated by the pixels of an input image. After being weighted and transformed by a function (determined by the network’s designer), the activations of these neurons are then passed on to other neurons. This process is repeated until finally, the output neuron that determines which character was read is activated.

The first study cited here relied on a standard multilayer perceptron (MLP), which is a feed forward artificial neural network model that maps sets of input data onto a set of appropriate outputs. In this instance, researchers worked with data from three cell lines (A549, MCF-7 and PC-3 cell lines from the LINCS project) that were treated with various compounds to elicit gene expression transcriptional profiles. Researchers began by classifying the compounds into therapeutic categories with DNN based solely on the transcriptional profiles. “After that we independently used both gene expression level data for “landmark genes” and pathway activation scores to train DNN classifier.” In total, the study analyzed 26,420 drug perturbation samples. Shown below is a representation of the DNN used in the drug study.

Study design: Gene expression data from LINCS Project was linked to 12 MeSH therapeutic use categories. DNN was trained separately on gene expression level data for “landmark genes” and pathway activation scores for significantly perturbed samples, forming an input layers of 977 and 271 neural nodes, respectively.
Study design: Gene expression data from LINCS Project was linked to 12 MeSH therapeutic use categories. DNN was trained separately on gene expression level data for “landmark genes” and pathway activation scores for significantly perturbed samples, forming an input layers of 977 and 271 neural nodes, respectively.

The details of the study are fascinating. Use of all the criteria was key to accuracy and the DNN effectiveness in coping with high dimensionality was a critical enabler.

In the second study, a more complicated ensemble approach proved most effective. Notably, this wasn’t a gene expression data analysis; rather it was based on blood-based markers. Data from roughly 60,000 blood samples from a single laboratory were analyzed. The five most predictive markers – albumin, glucose, alkaline phosphatase, urea, and erythrocytes – were identified. The best performing DNN achieved 81.5 percent accuracy, while the entire ensemble had 83.5 percent accuracy. The paper suggests the ensemble approach is likely most effective for integration of multimodal data and tracking of integrated biomarkers for aging.

DevBox_3qrtrOpen_wMonitorBoth studies required substantial compute power including the parallel processing capability of GPUs. NVIDIA assisted by providing early access to its DIGITS DevBox, which is a roughly 30Tflop deep learning machine featuring 4 Titan X GPU. “We also used a 2X Tesla K80 GPU system,” said Alex Zhavoronkov, an author on both papers and CEO of Insilico Medicine. “The original DNN in the molecular pharmaceutics [work] was trained on a Datalytics GPU cluster in New Mexico,” said Alex Zhavoronkov, CEO of Insilico Medicine and an author on both papers.

It bears repeating that Insilico Medicine was the main driver behind both papers and has a business interest in bolstering its credentials; that said, deep learning is a relatively small community where collaborations between academic, commercial, and technology suppliers are considerable. (For a snapshot of trends at the leading edge see HPCwire article, Beyond von Neumann, Neuromorphic Computing Steadily Advances.)

Insilico, founded in the 2014 timeframe, chose to focus on deep learning and signaling pathway activation analysis, which is an effective way to reduce dimensionality in gene expression data. “We are essentially a drug discovery engine now,” said Zhavoronkov, who has long been familiar with GPU technology having worked for several years at ATI Technologies. He’s also an ex-pat from Russia who has maintained close ties there; Insilico Medicine has grown to a staff of 39 including 22 in Moscow. Eleven are focused exclusively on deep learning.

Zhavoronkov divides the current deep learning community into three segments: one that is using off-the-shelf systems and tools; a second that is pushing the boundary and developing their own tools; and elite third components primarily focused on neural network R&D and developing new paradigms, citing Google DeepMind as one of the latter. “We fall into the middle category but also with domain expertise in drug discovery. There are few companies that have both.”

Perhaps predictably bullish, he said, “Both papers are first in class and demonstrate that deep learning can be very powerful in both drug discovery and biomarker development. In a short time we got over 800 strong hypotheses for both efficacy and toxicity of multiple drugs in many diseases.”

[i] Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data, Molecular Pharamaceutics, published by the American Chemical Society, http://pubs.acs.org/doi/abs/10.1021/acs.molpharmaceut.6b00248; the manuscript is now posted on the “Just Accepted” service of the ACS. Authors listed: Alexander Aliper, Sergey Plis, Artem Artemov, Alvaro Ulloa, Polina Mamoshina, Alex Zhavoronkov

[ii] Deep biomarkers of human aging: Application of deep neural networks to biomarker development, published in the May issue of Aging (Vol 8, No5), http://www.impactaging.com/papers/v8/n5/full/100968.html. Authors listed: Evgeny Putin, Polina Mamoshina, Alexander Aliper, Mikhail Korzinkin, Alexey Moskalev, Alexey Kolosov, Alexander Ostrovskiy, Charles Cantor, Jan Vijg, and Alex Zhavoronkov

Subscribe to HPCwire's Weekly Update!

Be the most informed person in the room! Stay ahead of the tech trends with industy updates delivered to you every week!

Quantum Riches and Hardware Diversity Are Discouraging Collaboration

November 28, 2022

Quantum computing is viewed as a technology for generations, and the spoils for the winners are huge, but the diversity of technology is discouraging collaboration, an Intel executive said last week. There are close t Read more…

2022 Road Trip: NASA Ames Takes Off

November 25, 2022

I left Dallas very early Friday morning after the conclusion of SC22. I had a race with the devil to get from Dallas to Mountain View, Calif., by Sunday. According to Google Maps, this 1,957 mile jaunt would be the longe Read more…

2022 Road Trip: Sandia Brain Trust Sounds Off

November 24, 2022

As the 2022 Great American Supercomputing Road Trip carries on, it’s Sandia’s turn. It was a bright sunny day when I rolled into Albuquerque after a high-speed run from Los Alamos National Laboratory. My interview su Read more…

2022 HPC Road Trip: Los Alamos

November 23, 2022

With SC22 in the rearview mirror, it’s time to get back to the 2022 Great American Supercomputing Road Trip. To refresh everyone’s memory, I jumped in the car on November 3rd and headed towards SC22 in Dallas, stoppi Read more…

Chipmakers Looking at New Architecture to Drive Computing Ahead

November 23, 2022

The ability to scale current computing designs is reaching a breaking point, and chipmakers such as Intel, Qualcomm and AMD are putting their brains together on an alternate architecture to push computing forward. The chipmakers are coalescing around the new concept of sparse computing, which involves bringing computing to data... Read more…

AWS Solution Channel

Shutterstock 110419589

Thank you for visiting AWS at SC22

Accelerate high performance computing (HPC) solutions with AWS. We make extreme-scale compute possible so that you can solve some of the world’s toughest environmental, social, health, and scientific challenges. Read more…

 

shutterstock_1431394361

AI and the need for purpose-built cloud infrastructure

Modern AI solutions augment human understanding, preferences, intent, and even spoken language. AI improves our knowledge and understanding by delivering faster, more informed insights that fuel transformation beyond anything previously imagined. Read more…

QuEra’s Quest: Build a Flexible Neutral Atom-based Quantum Computer

November 23, 2022

Last month, QuEra Computing began providing access to its 256-qubit, neutral atom-based quantum system, Aquila, from Amazon Braket. Founded in 2018, and built on technology developed at Harvard and MIT, QuEra, is one of Read more…

Quantum Riches and Hardware Diversity Are Discouraging Collaboration

November 28, 2022

Quantum computing is viewed as a technology for generations, and the spoils for the winners are huge, but the diversity of technology is discouraging collaborat Read more…

2022 HPC Road Trip: Los Alamos

November 23, 2022

With SC22 in the rearview mirror, it’s time to get back to the 2022 Great American Supercomputing Road Trip. To refresh everyone’s memory, I jumped in the c Read more…

QuEra’s Quest: Build a Flexible Neutral Atom-based Quantum Computer

November 23, 2022

Last month, QuEra Computing began providing access to its 256-qubit, neutral atom-based quantum system, Aquila, from Amazon Braket. Founded in 2018, and built o Read more…

SC22’s ‘HPC Accelerates’ Plenary Stresses Need for Collaboration

November 21, 2022

Every year, SC has a theme. For SC22 – held last week in Dallas – it was “HPC Accelerates”: a theme that conference chair Candace Culhane said reflected Read more…

Quantum – Are We There (or Close) Yet? No, Says the Panel

November 19, 2022

For all of its politeness, a fascinating panel on the last day of SC22 – Quantum Computing: A Future for HPC Acceleration? – mostly served to illustrate the Read more…

RISC-V Is Far from Being an Alternative to x86 and Arm in HPC

November 18, 2022

One of the original RISC-V designers this week boldly predicted that the open architecture will surpass rival chip architectures in performance. "The prediction is two or three years we'll be surpassing your architectures and available performance with... Read more…

Gordon Bell Special Prize Goes to LLM-Based Covid Variant Prediction

November 17, 2022

For three years running, ACM has awarded not only its long-standing Gordon Bell Prize (read more about this year’s winner here!) but also its Gordon Bell Spec Read more…

2022 Gordon Bell Prize Goes to Plasma Accelerator Research

November 17, 2022

At the awards ceremony at SC22 in Dallas today, ACM awarded the 2022 ACM Gordon Bell Prize to a team of researchers who used four major supercomputers – inclu Read more…

Nvidia Shuts Out RISC-V Software Support for GPUs 

September 23, 2022

Nvidia is not interested in bringing software support to its GPUs for the RISC-V architecture despite being an early adopter of the open-source technology in its GPU controllers. Nvidia has no plans to add RISC-V support for CUDA, which is the proprietary GPU software platform, a company representative... Read more…

RISC-V Is Far from Being an Alternative to x86 and Arm in HPC

November 18, 2022

One of the original RISC-V designers this week boldly predicted that the open architecture will surpass rival chip architectures in performance. "The prediction is two or three years we'll be surpassing your architectures and available performance with... Read more…

AWS Takes the Short and Long View of Quantum Computing

August 30, 2022

It is perhaps not surprising that the big cloud providers – a poor term really – have jumped into quantum computing. Amazon, Microsoft Azure, Google, and th Read more…

Chinese Startup Biren Details BR100 GPU

August 22, 2022

Amid the high-performance GPU turf tussle between AMD and Nvidia (and soon, Intel), a new, China-based player is emerging: Biren Technology, founded in 2019 and headquartered in Shanghai. At Hot Chips 34, Biren co-founder and president Lingjie Xu and Biren CTO Mike Hong took the (virtual) stage to detail the company’s inaugural product: the Biren BR100 general-purpose GPU (GPGPU). “It is my honor to present... Read more…

Tesla Bulks Up Its GPU-Powered AI Super – Is Dojo Next?

August 16, 2022

Tesla has revealed that its biggest in-house AI supercomputer – which we wrote about last year – now has a total of 7,360 A100 GPUs, a nearly 28 percent uplift from its previous total of 5,760 GPUs. That’s enough GPU oomph for a top seven spot on the Top500, although the tech company best known for its electric vehicles has not publicly benchmarked the system. If it had, it would... Read more…

AMD Thrives in Servers amid Intel Restructuring, Layoffs

November 12, 2022

Chipmakers regularly indulge in a game of brinkmanship, with an example being Intel and AMD trying to upstage one another with server chip launches this week. But each of those companies are in different positions, with AMD playing its traditional role of a scrappy underdog trying to unseat the behemoth Intel... Read more…

JPMorgan Chase Bets Big on Quantum Computing

October 12, 2022

Most talk about quantum computing today, at least in HPC circles, focuses on advancing technology and the hurdles that remain. There are plenty of the latter. F Read more…

Using Exascale Supercomputers to Make Clean Fusion Energy Possible

September 2, 2022

Fusion, the nuclear reaction that powers the Sun and the stars, has incredible potential as a source of safe, carbon-free and essentially limitless energy. But Read more…

Leading Solution Providers

Contributors

UCIe Consortium Incorporates, Nvidia and Alibaba Round Out Board

August 2, 2022

The Universal Chiplet Interconnect Express (UCIe) consortium is moving ahead with its effort to standardize a universal interconnect at the package level. The c Read more…

Nvidia, Qualcomm Shine in MLPerf Inference; Intel’s Sapphire Rapids Makes an Appearance.

September 8, 2022

The steady maturation of MLCommons/MLPerf as an AI benchmarking tool was apparent in today’s release of MLPerf v2.1 Inference results. Twenty-one organization Read more…

Not Just Cash for Chips – The New Chips and Science Act Boosts NSF, DOE, NIST

August 3, 2022

After two-plus years of contentious debate, several different names, and final passage by the House (243-187) and Senate (64-33) last week, the Chips and Science Act will soon become law. Besides the $54.2 billion provided to boost US-based chip manufacturing, the act reshapes US science policy in meaningful ways. NSF’s proposed budget... Read more…

SC22 Unveils ACM Gordon Bell Prize Finalists

August 12, 2022

Courtesy of the schedule for the SC22 conference, we now have our first glimpse at the finalists for this year’s coveted Gordon Bell Prize. The Gordon Bell Pr Read more…

Intel Is Opening up Its Chip Factories to Academia

October 6, 2022

Intel is opening up its fabs for academic institutions so researchers can get their hands on physical versions of its chips, with the end goal of boosting semic Read more…

AMD Previews 400 Gig Adaptive SmartNIC SOC at Hot Chips

August 24, 2022

Fresh from finalizing its acquisitions of FPGA provider Xilinx (Feb. 2022) and DPU provider Pensando (May 2022) ), AMD previewed what it calls a 400 Gig Adaptive smartNIC SOC yesterday at Hot Chips. It is another contender in the increasingly crowded and blurry smartNIC/DPU space where distinguishing between the two isn’t always easy. The motivation for these device types... Read more…

AMD’s Genoa CPUs Offer Up to 96 5nm Cores Across 12 Chiplets

November 10, 2022

AMD’s fourth-generation Epyc processor line has arrived, starting with the “general-purpose” architecture, called “Genoa,” the successor to third-gen Eypc Milan, which debuted in March of last year. At a launch event held today in San Francisco, AMD announced the general availability of the latest Epyc CPUs with up to 96 TSMC 5nm Zen 4 cores... Read more…

Google Program to Free Chips Boosts University Semiconductor Design

August 11, 2022

A Google-led program to design and manufacture chips for free is becoming popular among researchers and computer enthusiasts. The search giant's open silicon program is providing the tools for anyone to design chips, which then get manufactured. Google foots the entire bill, from a chip's conception to delivery of the final product in a user's hand. Google's... Read more…

  • arrow
  • Click Here for More Headlines
  • arrow
HPCwire